🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

Genovis AB (GENOb)

Stockholm
Currency in SEK
25.050
-0.600(-2.34%)
Closed
GENOb Scorecard
Full Analysis
Impressive gross profit margins
Fair Value
Day's Range
24.75025.500
52 wk Range
19.00053.900
Key Statistics
Edit
Prev. Close
25.65
Open
25.5
Day's Range
24.75-25.5
52 wk Range
19-53.9
Volume
49.66K
Average Volume (3m)
65.71K
1-Year Change
-51.36%
Book Value / Share
3.39
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GENOb Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
39.000
Upside
+55.689%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a high earnings multiple
Show more

Genovis AB Company Profile

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics for customers in the pharmaceutical and research industries. The company provides FabALACTICA, a cysteine protease; FabRICATOR, a cysteine protease; and FabRICATOR Z, for the digestion of mouse IgG2a and IgG3, and generating a homogenous pool of F(ab')2 and Fc fragments. It offers FabULOUS (SpeB), a cysteine protease; GingisKHAN, a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. In addition, the company offers GingisREX, a protease that digests proteins C-terminally of arginine residues; GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase; and OpeRATOR, an O-glycan-specific protease. Further, it provides OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of a-Fucosidases; GalactEXO, a ß-Galactosidase mix; GalNAcEXO, an a-N-Acetylgalactosaminidase; GlycOCATCH, an affinity resin; GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a goat polyclonal antibody; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody. Additionally, the company offers antibodies, assay kits, reagents, and cell culture products; bioprocess and gene therapy services; and services, such as SmartEnzymes fragmentation and conjugation, antibody LC-MS analysis, and customized antibody services, as well as operates an online store for its products. It serves pharmaceutical and biotech, contract research, and contract manufacturing companies in Europe, North America, and Asia. The company was founded in 1999 and is headquartered in Kävlinge, Sweden.

Compare GENOb to Peers and Sector

Metrics to compare
GENOb
Peers
Sector
Relationship
P/E Ratio
60.2x−1.3x−0.6x
PEG Ratio
−1.20−0.030.00
Price/Book
7.6x2.6x2.6x
Price / LTM Sales
12.9x4.7x3.2x
Upside (Analyst Target)
36.8%162.5%49.4%
Fair Value Upside
Unlock15.2%7.8%Unlock

Analysts' Recommendations

2 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 39.000

(+55.69% Upside)

FAQ

What Is the Genovis AB (GENOb) Stock Price Today?

The Genovis AB stock price today is 25.05

What Stock Exchange Does Genovis AB Trade On?

Genovis AB is listed and trades on the Stockholm stock exchange.

What Is the Stock Symbol for Genovis AB?

The stock symbol for Genovis AB is "GENOb."

What Is the Genovis AB Market Cap?

As of today, Genovis AB market cap is 1.64B.

What is Genovis AB Earnings Per Share?

The Genovis AB EPS is 0.426.

What Is the Next Genovis AB Earnings Date?

Genovis AB will release its next earnings report on 13 Feb 2025.

From a Technical Analysis Perspective, Is GENOb a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.